Status:

TERMINATED

Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Stress Urinary Incontinence

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

Background: Periurethral Pro-ACT balloons and retrourethral AdvanceXP(TM) male sling have been presented as efficient treatments for management of stress urinary incontinence (SUI) following radical p...

Detailed Description

Background: Stress urinary incontinence (SUI) is a common adverse event of radical prostatectomy (RP) for localized prostate cancer and can dramatically impact quality of life. Management of SUI after...

Eligibility Criteria

Inclusion

  • Age \> 18 years
  • Patient presenting mild to moderate stress urinary incontinence (20g \< 72 hours pad-test \< 300g) following radical prostatectomy more than 1 year ago.
  • Patient capable of roaming, independent and capable of using toilet without any trouble.
  • Patients able to answer to questionnaire and communicate in French
  • Informed consent
  • Patients with social security

Exclusion

  • Uncontrolled prostatic adenocarcinoma or PSA \> 1 ng/ml
  • Maximum urinary flow rate \< 15 ml/sec
  • Postvoid residual volume \> 150 ml
  • Urinated volume in 24h \> 3000 ml
  • Uninhibited detrusor contractions associated with leakage during the preoperative urodynamic assessment (realized under anticholinergic if the patient is usually under this medication)
  • Severe incontinence (Pad test \> 300g/24h)
  • History of artificial urinary sphincter
  • Known neurologic bladder dysfunction
  • History of neurological disease which can interfere with the urinary symptoms
  • Presence of a urethral stenosis or of an anastomotic stricture during the preoperative endoscopy.
  • Previous treatment with pelvic radiation therapy in 6 months before inclusion
  • Uncontrolled urinary tract infection
  • Patients affected by an infiltrative bladder tumour
  • Patients with bladder stones
  • Severe constitutional hemorrhagic disease or haemophilia
  • Deep depression of immune system
  • Severe renal impairment or obstructive pathology of the upper urinary tract with severe renal impairment

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2014

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT01500603

Start Date

March 1 2013

End Date

June 1 2014

Last Update

October 8 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Service d'urologie, Hôpital Tenon

Paris, France, 75020